Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06831916 · ClinicalTrials.gov registry record · Phase 2
Impact of Cannabinoids on Menopause Symptoms
A Phase 2 study of Menopause and Perimenopause, sponsored by Washington State University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06831916: Recruiting Phase 2 study of Menopause and Perimenopause, sponsored by Washington State University.
NCT06831916 is a Phase 2 study of Menopause and Perimenopause that is actively recruiting participants, run by Washington State University. The registered enrollment target is 100 participants, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06831916, a Phase 2 study of Menopause and Perimenopause, is actively recruiting participants, sponsored by Washington State University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to examine the impact of the hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
Primary Outcome
At the end of each monthly Zoom session, participants will be sent a survey link including the Beck Depression Inventory (BDI). Participants will complete the BDI after each zoom session, including the first session, the baseline session after four week, and after both phase 1 and phase 2.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Active Cannabinoid Product
Study Locations (1)
Washington
- Washington State University - Pullman Campus - Pullman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2027-01-12 |
| Phase | Phase 2 |
What NCT06831916 shows while recruiting
NCT06831916 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Menopause appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06831916 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06831916 about?
NCT06831916 is a clinical study titled "Impact of Cannabinoids on Menopause Symptoms". The purpose of the study is to examine the impact of the hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
What is the current status of trial NCT06831916?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-03-03. Estimated completion is 2027-01-12.
What conditions does trial NCT06831916 study?
This clinical trial studies the following conditions: Menopause, Perimenopause.
What interventions are being tested in trial NCT06831916?
The interventions under investigation include: Placebo (OTHER), Active Cannabinoid Product (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06831916?
This trial is sponsored by Washington State University, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06831916 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06831916's enrollment target sits among peer trials
100 19th of 54 higher than 33 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Anabolic Effect of Testosterone on Pelvic Floor Muscles
RECRUITING · Phase 2
-
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition
ACTIVE NOT RECRUITING · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
-
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
COMPLETED · Phase 2
-
A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI